ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 195,97
0,35%
Dow Jones
39 848,72
-0,39%
DAX
18 768,96
0,33%
Brent Oil
83,505
-0,11%
Bitcoin
68 814,76
4,02%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) Actualités

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BBIO
DateHeureSourceTitreSymboleSociété
17/05/202422h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
15/05/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
14/05/202413h30GlobeNewswire Inc.BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024NASDAQ:BBIOBridgeBio Pharma Inc
13/05/202413h30GlobeNewswire Inc.BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified SensitiNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
02/05/202413h00GlobeNewswire Inc.BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipelineNASDAQ:BBIOBridgeBio Pharma Inc
07/04/202419h15GlobeNewswire Inc.BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
06/03/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BBIOBridgeBio Pharma Inc
06/03/202423h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
06/03/202405h53GlobeNewswire Inc.BridgeBio Pharma Announces Pricing of Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202422h17GlobeNewswire Inc.BridgeBio Pharma Announces Proposed Public Offering of Common StockNASDAQ:BBIOBridgeBio Pharma Inc
04/03/202408h30GlobeNewswire Inc.BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
22/02/202422h27Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BBIOBridgeBio Pharma Inc
22/02/202413h30GlobeNewswire Inc.BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:BBIOBridgeBio Pharma Inc
15/02/202422h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
13/02/202422h05Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
07/02/202413h34GlobeNewswire Inc.BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in JapanNASDAQ:BBIOBridgeBio Pharma Inc
05/02/202413h30GlobeNewswire Inc.BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
02/02/202413h00GlobeNewswire Inc.BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 MonthsNASDAQ:BBIOBridgeBio Pharma Inc
30/01/202413h00PR Newswire (US)Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsNASDAQ:BBIOBridgeBio Pharma Inc
18/01/202413h00GlobeNewswire Inc.BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic MedicinesNASDAQ:BBIOBridgeBio Pharma Inc
10/01/202423h15GlobeNewswire Inc.BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of MedicineNASDAQ:BBIOBridgeBio Pharma Inc
05/01/202422h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BBIOBridgeBio Pharma Inc
03/01/202422h30GlobeNewswire Inc.BridgeBio Pharma to Participate in the J.P. Morgan Healthcare ConferenceNASDAQ:BBIOBridgeBio Pharma Inc
03/01/202413h30GlobeNewswire Inc.BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)NASDAQ:BBIOBridgeBio Pharma Inc
13/12/202313h30GlobeNewswire Inc.BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with AchondroplasiaNASDAQ:BBIOBridgeBio Pharma Inc
05/12/202314h52Dow Jones NewsBridgeBio Seeks FDA Approval of Acoramidis in Transthyretin Amyloid CardiomyopathyNASDAQ:BBIOBridgeBio Pharma Inc
05/12/202313h44GlobeNewswire Inc.BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
12/11/202316h30GlobeNewswire Inc.BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
09/11/202313h30GlobeNewswire Inc.BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023NASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Dernières Valeurs Consultées

EU
CDCLC
CDC Habitat SA 1.275% un...
NASDAQ
AVBP
ArriVent BioPharma
BIT
P1XKY2
NLBNPIT1XKY2 20240920 60
AMEX
UBT
ProShares Ultra 20 Plus ...
BIT
P20WE7
NLBNPIT20WE7 20241220 26
EU
FR0128428952
CA Consumer Finance Cacf...
EU
ACART
Credit Agricole Sa Casa4...
BOV
C2OI34
Coinbase Global
USOTC
BTGGF
Bitcoin (PK)
USOTC
YDGHF
Yadong (PK)
EU
XS1683357252
Ing Groep NV 4% 14sep2032
TG
BS84
Deutschland Bundesrepublik
BIT
P1W924
NLBNPIT1W924 20240621 340
COIN
OPENNGBP
OPEN Platform
BOV
VITT3F
Vittia ON
TSXV
NZ
New Zealand Energy
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés